Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01077297 · ClinicalTrials.gov registry record · Phase 2
Tezosentan in Pulmonary Arterial Hypertension
A Phase 2 study, sponsored by Idorsia Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT01077297: Clinical Trial Phase 2 study, sponsored by Idorsia Pharmaceuticals.
NCT01077297 is a Phase 2 study that was terminated before completion, run by Idorsia Pharmaceuticals. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01077297, a Phase 2 study, was terminated before completion, sponsored by Idorsia Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
Multicenter, Open-label, Non-comparative, Proof-of-concept, Phase 2a Study to Evaluate the Effect of a Single Infusion of Tezosentan on Pulmonary Vascular Resistance in Patients With Stable, Chronic Pulmonary Arterial Hypertension, Currently Not Treated With Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors or Prostacyclines
Interventions
- DRUG Tezosentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2010-08 |
| Est. Completion | 2011-09 |
| Phase | Phase 2 |
Why NCT01077297 stopped before completion
NCT01077297 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Tezosentan is the first listed.
NCT01077297 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01077297 about?
NCT01077297 is a clinical study titled "Tezosentan in Pulmonary Arterial Hypertension". Multicenter, Open-label, Non-comparative, Proof-of-concept, Phase 2a Study to Evaluate the Effect of a Single Infusion of Tezosentan on Pulmonary Vascular Resistance in Patients With Stable, Chronic Pulmonary Arterial Hypertension, Currently Not Treated With Endothelin Receptor Antagonists, Phosphod...
What is the current status of trial NCT01077297?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2010-08. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01077297?
The interventions under investigation include: Tezosentan (DRUG).
Who is sponsoring clinical trial NCT01077297?
This trial is sponsored by Idorsia Pharmaceuticals, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01077297's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia